文献速递肝病

在大型非酒精性脂肪性肝病真实世界队列中验证基于临床风险的分层系统

Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-03-05

本研究在TARGET-NASH纵向非干预研究中回顾-前瞻性分析2523例非酒精性脂肪性肝病(NAFLD)患者,按FIB-4和/或肝硬度测量分为A、B、C三组,中位随访3.74年。结果示全因死亡率、肝脏相关临床事件、主要不良心血管事件、肝细胞癌和慢性肾病发生率随风险等级升高而增加;因天冬氨酸转氨酶:丙氨酸转氨酶比值>1或血小板<150,000/mm3而升级者的结局率与按FIB-4定义的较低等级相似。作者认为数据支持基于FIB-4的NAFLD风险分层可用于常规临床实践。

要点

  • 按FIB-4和/或肝硬度测量将NAFLD患者分为A、B、C三组,中位随访3.74年。
  • 全因死亡率、肝脏相关临床事件、主要不良心血管事件、肝细胞癌和慢性肾病发生率从A组到C组增加。
  • 因天冬氨酸转氨酶:丙氨酸转氨酶比值>1或血小板<150,000/mm3而升级者的结局率与按FIB-4定义的较低等级相似。

核心结论

  • 这些数据支持基于FIB-4的NAFLD风险分层可用于常规临床实践。

研究设计与样本

  • 对纳入纵向非干预研究(TARGET-NASH)的NAFLD患者进行回顾-前瞻性分析,共2523人(A组555人、B组879人、C组1089人),中位随访3.74年。
  • 风险分类:A组FIB-4<1.3和/或Fibroscan肝硬度测量<8 kp;B组FIB-4 1.31‒2.6和/或肝硬度测量8.1-12.5 kp;C组FIB-4>2.6和/或肝硬度测量>12.5 kp。
  • A组中天冬氨酸转氨酶:丙氨酸转氨酶比值>1或血小板<150,000/mm3者,或B组中天冬氨酸转氨酶:丙氨酸转氨酶比值>1或血小板<150,000/mm3者,升级一个等级。
  • 对所有结局进行Fine-Gray竞争风险分析。

主要发现

  • 全因死亡率:A组0.07/100人年 vs B组0.3/100人年 vs C组2.5/100人年;B组 vs A组HR 3.0,C组 vs A组HR 16.3。
  • 肝脏相关临床事件:A组0.2/100人年 vs B组1/100人年 vs C组8/100人年;B组 vs A组HR 4.3,C组 vs A组HR 36.6。
  • 主要不良心血管事件:A组0.69/100人年 vs B组0.87/100人年 vs C组2.02/100人年;B组 vs A组HR 0.78,C组 vs A组HR 1.55。
  • 肝细胞癌:A组0/100人年 vs B组0.09/100人年 vs C组0.88/100人年;C组 vs B组HR 8.32。
  • 慢性肾病:A组1.24/100人年 vs B组2.48/100人年 vs C组3.51/100人年。

临床怎么用

  • 作者认为这些数据支持基于FIB-4的NAFLD风险分层可用于常规临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There is an unmet need to validate simple and easily available methods that can be used in routine practice to identify those at risk of adverse outcomes from nonalcoholic fatty liver disease (NAFLD). A retrospective-prospective analysis of NAFLD patients enrolled in a longitudinal noninterventional study (TARGET-NASH) was performed to validate the prognostic utility of the following risk-categories: (A) Fibrosis-4 (FIB-4) <1.3 and/or liver-stiffness measurement (LSM) measured by Fibroscan <8 kp, (B) FIB-4 1.31‒2.6 and/or LSM 8.1-12.5 kp, and (C) FIB-4 >2.6 and/or LSM >12.5 kp. METHODS: Those in class A with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3, or class B with aspartate transaminase:alanine transaminase ratio >1 or platelets <150,000/mm3 were upstaged by one class. Fine-Gray competing risk analyses were performed for all outcomes. RESULTS: A total of 2523 individuals (class A = 555, B = 879, C = 1089) were followed for a median duration of 3.74 years. Adverse outcomes increased from class A to C in all-cause mortality (0.07 vs 0.3 vs 2.5/100 person-years [PY], hazard ratio [HR], 3.0 and 16.3 class B and C vs A), liver-associated clinical events (0.2 vs 1 vs 8/100 PY, HR, 4.3 and 36.6 B and C vs A), major adverse cardiovascular events (0.69 vs 0.87 vs 2.02/100 PY, HR, 0.78 and 1.55 B and C vs A), hepatocellular carcinoma (0 vs 0.09 vs 0.88/100 PY, HR, 8.32 C vs B), and chronic kidney disease (1.24 vs 2.48 vs 3.51/100 PY). Those who were upstaged had outcome rates similar to the lower class defined by their FIB-4. CONCLUSIONS: These data support a FIB-4-based risk-stratification of NAFLD that can be used in routine clinical practice. CLINICALTRIALS: gov Identifier: NCT02815891.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sanyal AJ, Munoz B, Cusi K, et al. Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort. Clin Gastroenterol Hepatol. 2023. PMID: 36871772. doi:10.1016/j.cgh.2023.02.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。